IGC Pharma annual gross profit
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma Gross Profit Growth & History (IGC)
IGC Pharma's gross profit was $297,000 for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | $297,000 | — | — |
| 2025 · Mar 31 | 2025-03-31 | $619,000 | −$114,000 | −15.55% |
| 2024 | 2024-03-31 | $733,000 | $291,000 | +65.84% |
| 2023 | 2023-03-31 | $442,000 | $248,000 | +127.84% |
| 2022 | 2022-03-31 | $194,000 | $81,000 | +71.68% |
| 2021 | 2021-03-31 | $113,000 | −$2,000 | −1.74% |
| 2020 | 2020-03-31 | $115,000 | −$17,000 | −12.88% |
| 2019 | 2019-03-31 | $132,000 | $50,000 | +60.98% |
| 2018 | 2018-03-31 | $82,000 | −$136,237 | −62.43% |
| 2017 | 2017-03-31 | $218,237 | −$625,057 | −74.12% |
| 2016 | 2016-03-31 | $843,294 | $263,605 | +45.47% |
| 2015 | 2015-03-31 | $579,689 | $198,093 | +51.91% |
| 2014 | 2014-03-31 | $381,596 | −$1.2M | −75.11% |
| 2013 | 2013-03-31 | $1.5M | $2.2M | — |
| 2012 | 2012-03-31 | −$618,429 | −$777,693 | — |
| 2011 | 2011-03-31 | $159,264 | — | — |
IGC Pharma quarterly gross profit
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | $48,000 | −$106,000 | −68.83% |
| Q1 2026 · Mar 31 | 2026-03-31 | $55,000 | −$99,000 | −64.29% |
| Q4 2025 | 2025-12-31 | −$110,000 | −$214,000 | — |
| Q2 2026 · Sep 30 | 2025-09-30 | $99,000 | −$99,000 | −50.00% |
| Q1 2026 · Jun 30 | 2025-06-30 | $154,000 | −$9,000 | −5.52% |
| Q4 2025 | 2025-03-31 | $154,000 | −$17,000 | −9.94% |
| Q3 2025 | 2024-12-31 | $104,000 | −$29,000 | −21.80% |
| Q2 2025 | 2024-09-30 | $198,000 | $24,000 | +13.79% |
| Q1 2025 | 2024-06-30 | $163,000 | −$92,000 | −36.08% |
| Q4 2024 | 2024-03-31 | $171,000 | $108,000 | +171.43% |
| Q3 2024 | 2023-12-31 | $133,000 | $31,000 | +30.39% |
| Q2 2024 | 2023-09-30 | $174,000 | $39,000 | +28.89% |
| Q1 2024 | 2023-06-30 | $255,000 | $113,000 | +79.58% |
| Q4 2023 | 2023-03-31 | $63,000 | −$5,000 | −7.35% |
| Q3 2023 | 2022-12-31 | $102,000 | $40,000 | +64.52% |
| Q2 2023 | 2022-09-30 | $135,000 | $97,000 | +255.26% |
| Q1 2023 | 2022-06-30 | $142,000 | $116,000 | +446.15% |
| Q4 2022 | 2022-03-31 | $68,000 | $41,000 | +151.85% |
| Q3 2022 | 2021-12-31 | $62,000 | $48,000 | +342.86% |
| Q2 2022 | 2021-09-30 | $38,000 | $12,000 | +46.15% |
| Q1 2022 | 2021-06-30 | $26,000 | −$20,000 | −43.48% |
| Q4 2021 | 2021-03-31 | $27,000 | $11,000 | +68.75% |
| Q3 2021 | 2020-12-31 | $14,000 | −$16,000 | −53.33% |
| Q2 2021 | 2020-09-30 | $26,000 | −$2,000 | −7.14% |
| Q1 2021 | 2020-06-30 | $46,000 | $5,000 | +12.20% |
| Q4 2020 | 2020-03-31 | $16,000 | −$11,000 | −40.74% |
| Q3 2020 | 2019-12-31 | $30,000 | −$15,000 | −33.33% |
| Q2 2020 | 2019-09-30 | $28,000 | $10,000 | +55.56% |
| Q1 2020 | 2019-06-30 | $41,000 | −$1,000 | −2.38% |
| Q4 2019 | 2019-03-31 | $27,000 | $102,046 | — |
| Q3 2019 | 2018-12-31 | $45,000 | $6,000 | +15.38% |
| Q2 2019 | 2018-09-30 | $18,000 | −$54,000 | −75.00% |
| Q1 2019 | 2018-06-30 | $42,000 | −$4,046 | −8.79% |
| Q4 2018 | 2018-03-31 | −$75,046 | −$7,043 | — |
| Q3 2018 | 2017-12-31 | $39,000 | −$88,972 | −69.52% |
| Q2 2018 | 2017-09-30 | $72,000 | $371 | +0.52% |
| Q1 2018 | 2017-06-30 | $46,046 | −$40,593 | −46.85% |
| Q4 2017 | 2017-03-31 | −$68,003 | −$335,270 | — |
| Q3 2017 | 2016-12-31 | $127,972 | −$78,028 | −37.88% |
| Q2 2017 | 2016-09-30 | $71,629 | −$94,358 | −56.85% |
| Q1 2017 | 2016-06-30 | $86,639 | −$117,401 | −57.54% |
| Q4 2016 | 2016-03-31 | $267,267 | $144,587 | +117.86% |
| Q3 2016 | 2015-12-31 | $206,000 | $6,870 | +3.45% |
| Q2 2016 | 2015-09-30 | $165,987 | −$15,316 | −8.45% |
| Q1 2016 | 2015-06-30 | $204,040 | $127,464 | +166.45% |
| Q4 2015 | 2015-03-31 | $122,680 | $128,581 | — |
| Q3 2015 | 2014-12-31 | $199,130 | $189,390 | +1944.46% |
| Q2 2015 | 2014-09-30 | $181,303 | −$8,789 | −4.62% |
| Q1 2015 | 2014-06-30 | $76,576 | −$111,089 | −59.20% |
| Q4 2014 | 2014-03-31 | −$5,901 | −$221,725 | — |
| Q3 2014 | 2013-12-31 | $9,740 | −$734,216 | −98.69% |
| Q2 2014 | 2013-09-30 | $190,092 | −$53,017 | −21.81% |
| Q1 2014 | 2013-06-30 | $187,665 | −$142,571 | −43.17% |
| Q4 2013 | 2013-03-31 | $215,824 | $890,771 | — |
| Q3 2013 | 2012-12-31 | $743,956 | $781,974 | — |
| Q2 2013 | 2012-09-30 | $243,109 | $234,511 | +2727.51% |
| Q1 2013 | 2012-06-30 | $330,236 | $244,298 | +284.27% |
| Q4 2012 | 2012-03-31 | −$674,947 | −$593,620 | — |
| Q3 2012 | 2011-12-31 | −$38,018 | −$64,745 | — |
| Q2 2012 | 2011-09-30 | $8,598 | −$60,235 | −87.51% |
| Q1 2012 | 2011-06-30 | $85,938 | −$59,093 | −40.75% |
| Q4 2011 | 2011-03-31 | −$81,327 | — | — |
| Q3 2011 | 2010-12-31 | $26,727 | — | — |
| Q2 2011 | 2010-09-30 | $68,833 | — | — |
| Q1 2011 | 2010-06-30 | $145,031 | — | — |
IGC Pharma gross profit trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's gross profit increased from $159,264 to $297,000, a change of $137,736. The latest reported quarter, Q2 2026 · Jun 30, shows $48,000.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗